RxDoctor Payments Data

Abigail Richardson

Family · Huntington, WVNPI 1124648670

Payments from drug & device makers

$4,709in general payments, 2019–2025

Across 172 payments — averaging $27.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • GSK$592
  • AstraZeneca$439
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$390
  • Novo Nordisk$296
  • Sanofi-aventis U.S. LLC$156
  • plus $529 from 15 others

What the payments were for

  • Food & beverage$4,709100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,709 in reported general payments places this provider in the 90th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$6,459
Medicare patients
22
Services billed
92

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide32$49,291
VascepaIcosapent Ethyl13$7,455
Oxybutynin Chloride ErOxybutynin Chloride20$1,692
Albuterol Sulfate HfaAlbuterol Sulfate15$981
Clonazepam68$968
Pregabalin29$913
Acetaminophen-CodeineAcetaminophen With Codeine15$686
Gabapentin56$575
Levothyroxine Sodium44$559
Quetiapine Fumarate17$520
Tramadol Hcl25$388
Olmesartan Medoxomil11$375
Atorvastatin Calcium26$365
Omeprazole32$365
Famotidine26$341

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$46$49,29132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,507 family providers in West Virginia.

Other family in Huntington

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →